{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:01:01Z","timestamp":1761541261927},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T00:00:00Z","timestamp":1433203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>Inhibitor development in haemophilia patients is challenging especially when undergoing surgical procedures. The development of an inhibitor precludes using factor VIII (FVIII) therapy thereby requiring a bypassing agent (<jats:styled-content style=\"fixed-case\">BPA<\/jats:styled-content>) for surgical bleeding prophylaxis if the FVIII inhibitor titre &gt;5\u00a0BU. Concomitant use of anti\u2010inhibitor coagulant complex (<jats:styled-content style=\"fixed-case\">AICC<\/jats:styled-content>) and tranexamic acid has been reported in the literature as a beneficial treatment for this population. Anti\u2010inhibitor coagulant complex is known to cause an increase in thrombin generation and tranexamic acid inhibits fibrinolysis. Hence, the combined used of <jats:styled-content style=\"fixed-case\">AICC<\/jats:styled-content> and tranexamic acid has been limited due to safety concerns over possibilities of increased risk of thrombotic events and disseminated intravascular coagulation. However, the rationale for concomitant therapy is to obtain a potential synergistic effect and to increase clot stability. We conducted a literature review of past studies and individual case reports of concomitant use of <jats:styled-content style=\"fixed-case\">AICC<\/jats:styled-content> and tranexamic acid, which was extensively used during dental procedures. Evidence also exists for concomitant use of the combined therapy in orthopaedic procedures, control of gastrointestinal bleeding, epistaxis and cerebral haemorrhages. Some patients who received the combined therapy had failed monotherapy with a single <jats:styled-content style=\"fixed-case\">BPA<\/jats:styled-content> prior to combined therapy. There were no reports of thrombotic complications related to the concomitant therapy and haemostasis was achieved in all cases. Anti\u2010inhibitor coagulant complex and tranexamic acid therapy was found to be safe, well\u2010tolerated and effective therapy in haemophilia patients with inhibitors. Additional randomized controlled studies should be performed to confirm these findings.<\/jats:p>","DOI":"10.1111\/hae.12723","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T23:39:09Z","timestamp":1433374749000},"page":"709-714","source":"Crossref","is-referenced-by-count":17,"title":["Should anti\u2010inhibitor coagulant complex and tranexamic acid be used concomitantly?"],"prefix":"10.1111","volume":"21","author":[{"given":"L. A.","family":"Valentino","sequence":"first","affiliation":[{"name":"Rush University Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. A.","family":"Holme","sequence":"additional","affiliation":[{"name":"Research Institute of Internal Medicine Institute of Clinical Medicine Oslo Norway"},{"name":"Department of Hematology Oslo University Hospital Rikshospitalet Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1754-4505.1986.tb01000.x"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02748.x"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199509000-00011"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00242.x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01359.x"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20474"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12049"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01379.x"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/9780470987124.ch11","volume-title":"Textbook of Hemophilia","author":"DiMichele D","year":"2005"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(08)70001-8"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470312"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00924.x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01840.x"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00299.x"},{"key":"e_1_2_12_17_1","first-page":"181","volume-title":"Activated Prothrombin Complex Concentrates. Managing Hemophilia with Factor VIII Inhibitor","author":"Scharrer I","year":"1982"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2011.03.015"},{"key":"e_1_2_12_19_1","volume-title":"Anti\u2010Inhibitor Coagulant Complex","author":"Feiba","year":"2013"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00934.x"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.33.Suppl_14.50"},{"key":"e_1_2_12_22_1","first-page":"e944","article-title":"Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma","volume":"2011","author":"Dai L","year":"2011","journal-title":"Haemophilia"},{"key":"e_1_2_12_23_1","first-page":"1","article-title":"Bypassing agent therapy with and without tranexamic acid in haemophilia a patients with inhibitors \u2013 an in\u2010vivo prospective crossover study","volume":"1","author":"Tran HTT","year":"2013","journal-title":"Lancet"},{"key":"e_1_2_12_24_1","volume-title":"Safe Concurrent Use of Intravenous or Oral Tranexamic Acid and APCC in Patients with Haemophilia Complicated by High\u2010Titer Inhibitors","author":"Stefanska\u2010Windyga E","year":"2012"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1978.tb01039.x"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(80)90211-X"},{"key":"e_1_2_12_27_1","first-page":"168","volume-title":"Activated Prothrombin Complex Concentrates: Managing Hemophilia with FactorVIII Inhibitor","author":"Agrestini F","year":"1982"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12080"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00857.x"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199705000-00195"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01367.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12723","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:30:06Z","timestamp":1695562206000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,2]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/hae.12723"],"URL":"https:\/\/doi.org\/10.1111\/hae.12723","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,2]]}}}